Education
About Us
Working with TipRanks
Follow Us
Zymeworks (ZYME)
:ZYME
ZYME Stock Chart & Stats
$16.46
-$0.11(-0.77%)
At close: 4:00 PM EST
$16.46
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$9.03 - $19.98
Previous CloseN/A
Volume35.38K
Average Volume (3M)819.64K
Market Cap
$1.37B
Enterprise ValueN/A
Total Cash (Recent Filing)$251.93B
Total Debt (Recent Filing)$18.90B
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 11, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding75,166,200
10 Day Avg. Volume1,091,390
30 Day Avg. Volume819,642
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)3.28
Price to Sales (P/S)14.55
P/FCF Ratio-9.82
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$25.75Price Target Upside56.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$137.29M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsZW191 demonstrated promising early Ph1 data, highlighting best-in-class potential and a clean safety profile that is differentiated from competitor FRα ADCs.
Pipeline ProgressZymeworks reported solid progress in Q3 for Ziihera and its wholly owned pipeline.
Regulatory ApprovalsZiihera sales are picking up in 2L HER2+ BTC, and approvals in China and Europe for this indication further support growth.
Bears Say
Clinical Trial ChallengesRisks include potential clinical trial failures, safety issues, and the inability to scale up manufacturing, which could impact Zymeworks' future performance.
Comparison With CompetitorsInvestors will inevitably try to compare against updated data from competitor FRɑ ADCs, such as LLY's LY4170156 and AZD5335.
Competitive RisksSeveral other competitors are advancing FRa-targeted ADCs, posing a competitive risk for Zymeworks.
Zymeworks News
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $9.03 and its highest was $19.98 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.37B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Mar 11, 2026 which is in 123 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.295 by $0.035.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.53.
How many shares outstanding does Zymeworks have?
Zymeworks has 75,166,200 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.295. Following the earnings report the stock price went down -8.045%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.75 (56.44% Upside)
$25.75 (56.44% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 733.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 18.2%
Last 30 Days ▲ 18.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.84%
12-Months-Change
Fundamentals
Return on Equity
-19.89%
Trailing 12-Months
Asset Growth
-20.80%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of strong revenue growth and promising clinical data that suggest a positive outlook for Zymeworks. However, the discontinuation of a key program and the decrease in cash reserves present challenges. The sentiment is largely buoyed by the revenue increase and positive clinical trial results.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$25.75
▲(56.44% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
31.38% Insiders
7.07% Mutual Funds
1.77% Other Institutional Investors
47.03% Public Companies and
Individual Investors